THE proliferation rate of vascular endothelial cells in tumours exceeds that in most adult normal tissues by a very large factor, often greater than 20 ( Figure) . This enormous differential offers a potential route for aiming tumour therapy at solid tumours by means of a targeted systemic toxin, with little risk of damage to most of the normal tissues.
It has long been recognized that one of the major differences between solid tumours and adult normal tissues is the pattern and rate of development of the vascular network. New vessel formation in tumours is rapid, but it is insufficient, particularly in a 3-dimensional arrangement, to provide an adequate nutrient supply to all the tumour cells (Hirst et al., 1982) . For this reason many tumour cells are non-proliferating because of nutrient deprivation, and hypoxic because of oxygen depletion by the metabolizing tumour cells around each capillary. This produces resistance to both chemotherapy and radiotherapy. A great deal of research is devoted to finding ways of improving the oxygenation, proliferative status and drug delivery in such tumours.
Folkman and co-workers (Folkman et al., 1971; Folkman, 1974 Folkman, , 1975 have recognized the special ability of tumour cells to promote new vessel formation via the tumour angiogenesis factor (TAF). They have proposed methods ofpreventing tumour growth by interfering with angiogenesis, including an immunological technique for inactivating TAF by producing an anti-TAF antibody which would prevent further capillary proliferation.
Elsewhere, little attention has been paid to the enormous differential between the proliferation characteristics of the tumour vasculature and the normal tissue vasculature. Tannock (1970) , Hirst & Denekamp (1979) and Hirst et al. (1982) have compared the proliferation rate of the capillary endothelium in tumours with that of the tumour cells themselves. They concluded that the rate of endothelial proliferation limits tumour cell production even though as many as 18% of the endothelial cells can be in DNA synthesis at any one time.
Other studies have concentrated on the very low proliferation rate of endothelial cells in a variety of normal tissues (see reviews by Tannock & Hayashi, 1972; Hirst et al., 1980) . However, the remarkable difference in proliferation rates between endothelium in tumours and in normal tissues does not seem to have been previously commented upon or identified as a potential route for directing therapy at a tumour.
The Table summarizes Tannock, 1970 Hirst et al., 1982 The potential turnover time is calculated as ATs/LI (assuming A = 0-8 and Ts = 10 h) where A is a correction factor for the non-linear distribution of cells throughout the phases of the cell cycle (Steel, 1968) . Tannock & Hayashi (1972) and Hirst et al. (1980) for a wide range of normal tissues. It does not differ much between major vessels and capillaries. Most authors have indicated extremely low proliferative activity in normal tissue endothelium, with half the studies showing an LI <0.25%.
The highest recorded value is 3.4% for adult rat mesenteric vessels (Crane & Dutta, 1964) but this contrasts markedly with 0.45% for the same tissue in mice . Fewer data have been published for tumours; these are also summarized in the Table. The lowest LI is 4.5% for the exceptionally slow-growing mouse tumour CA RH (Hirst et al., 1982) and two of the tumours have values approaching 18%. This difference between tumours and normal tissues is illustrated even more dramatically in the Figure. Some additional data are included for rat and mouse tumours (Denekamp & Hobson, in preparation) which show a range from 3.5% for lymphoma KHAA (which grows by infiltration rather than by evoking a neovasculature) to 32.5% for the rapidly growing rat fibrosarcoma RIB5. The mean of the endothelial LI values in tumours is more than 20-fold that for normal tissues and there is hardly any overlap of the histograms.
With the advent of sophisticated immunological techniques, including monoclonal antibodies, it seems likely that (Hoyer et al., 1973) and monoclonal antibodies have recently been raised against this antigen (Sola et al., 1981) . It should be possible to conjugate an S-phase-specific chemotherapeutic agent with an endothelial-cell-specific antibody, which could result in a large degree of cell killing in tumour capillaries with very little damage to any normal tissue vessels. It is also conceivable that antibodies could be raised more specifically against proliferating endothelial cells, as distinct from all other endothelial cells. These could then be conjugated with any potent cell toxin (e.g. abrin or ricin) which would be released at the desired site of action. Proliferating endothelial cells can be produced very readily in vivo as a granulomatous response to an irritant; this would provide a richer and easier source of dividing endothelium than tumour vessels for raising antibodies This approach, directing tumour therapy via the proliferating endothelium, would avoid the necessity for identifying a tumour-specific antigen. It could provide a means of attacking solid tumours, including small metastases, via a universal pathway which is already known to be the weak point in tumour development. It would need to be used in combination with radiation and/or chemotherapy, and the sequencing would be very important. As vessels become occluded or collapse the surrounding cells would become more deficient in nutrients and oxygen and hence more chemo-and radiation-resistant. The possible influx of endothelial cells from the general circulation would also need to be studied, but this seems to be a relatively slow process . Potential side effects, of course, would need a very thorough investigation in animals. Fresh wound tissue, premenopausal endometrium and placenta, are all tissues in which a highlv proliferative endothelium will exist, and these would probably be at risk. Patients undergoing surgery, pregnant women, or those in the initial proliferative phase of each oestrus cycle, would therefore be unsuitable for this form of therapy. However, antiproliferating-endothelium therapy (APET) would be likely to be of only a few days duration to injure most of the tumour endothelium, as judged from the potential turnover-time estimates for tumour endothelium, at least for rodent tumours (Table) . The demonstration of equally high Lls for endothelium in human tumours would of course be crucial for this approach to have a clinical future. This information should be readily obtainable with biopsy material and in vitro incubation (Denekamp & Kallman, 1973) .
A small loss of endothelial cells in normal tissues is unlikely to be of major significance. Radiation studies on mesenteric arterioles have shown that the endothelium can be gradually depleted to 10-20% of its normal cell number without any thrombosis or failure of vessel function. . This functional reserve probably results from the welldeveloped sub-endothelial layers in normal blood vessels, which are notably lacking in most tumour vessels. It is not known how catastrophic the loss of 50% or 90% of the tumour endothelial cells would be, but it is possible that the already poor nturient supply would collapse and lead to massive tumour-cell necrosis.
We are currently studying a variety of other tumours and normal tissues. We are using repeated doses of [3H]dT to determine how many sequential injections are needed to label all the endothelial cells. Preliminary data indicate that the 20-fold difference between tumour and normal vessels persists after one week of continuous labelling (Denekamp & Hobson unpublished) . From these data it should be possible to predict how long an APET treatment with an S-phase-specific endothelial toxin would be needed to affect a given proportion of the endothelial cells in tumour capillaries. 
